AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 129.00 Decreased By ▼ -0.53 (-0.41%)
BOP 6.76 Increased By ▲ 0.08 (1.2%)
CNERGY 4.50 Decreased By ▼ -0.13 (-2.81%)
DCL 8.70 Decreased By ▼ -0.24 (-2.68%)
DFML 41.00 Decreased By ▼ -0.69 (-1.66%)
DGKC 81.30 Decreased By ▼ -2.47 (-2.95%)
FCCL 32.68 Decreased By ▼ -0.09 (-0.27%)
FFBL 74.25 Decreased By ▼ -1.22 (-1.62%)
FFL 11.75 Increased By ▲ 0.28 (2.44%)
HUBC 110.03 Decreased By ▼ -0.52 (-0.47%)
HUMNL 13.80 Decreased By ▼ -0.76 (-5.22%)
KEL 5.29 Decreased By ▼ -0.10 (-1.86%)
KOSM 7.63 Decreased By ▼ -0.77 (-9.17%)
MLCF 38.35 Decreased By ▼ -1.44 (-3.62%)
NBP 63.70 Increased By ▲ 3.41 (5.66%)
OGDC 194.88 Decreased By ▼ -4.78 (-2.39%)
PAEL 25.75 Decreased By ▼ -0.90 (-3.38%)
PIBTL 7.37 Decreased By ▼ -0.29 (-3.79%)
PPL 155.74 Decreased By ▼ -2.18 (-1.38%)
PRL 25.70 Decreased By ▼ -1.03 (-3.85%)
PTC 17.56 Decreased By ▼ -0.90 (-4.88%)
SEARL 78.71 Decreased By ▼ -3.73 (-4.52%)
TELE 7.88 Decreased By ▼ -0.43 (-5.17%)
TOMCL 33.61 Decreased By ▼ -0.90 (-2.61%)
TPLP 8.41 Decreased By ▼ -0.65 (-7.17%)
TREET 16.26 Decreased By ▼ -1.21 (-6.93%)
TRG 58.60 Decreased By ▼ -2.72 (-4.44%)
UNITY 27.51 Increased By ▲ 0.08 (0.29%)
WTL 1.41 Increased By ▲ 0.03 (2.17%)
BR100 10,450 Increased By 43.4 (0.42%)
BR30 31,209 Decreased By -504.2 (-1.59%)
KSE100 97,798 Increased By 469.8 (0.48%)
KSE30 30,481 Increased By 288.3 (0.95%)
World

South Korea reels from most daily COVID-19 cases in 3 months, approves Johnson & Johnson vaccine

  • J&J is the third COVID-19 vaccine maker to be authorised in South Korea, after AstraZeneca and Pfizer, both of which require two doses.
Published April 7, 2021

SEOUL: South Korea on Wednesday reported its highest single-day number of new coronavirus cases in three months amid a rise in cluster infections, as it approved a Johnson & Johnson vaccine in a bid to expedite its inoculation campaign.

The Korea Disease Control and Prevention Agency (KDCA) reported 668 new cases for Tuesday, the highest level since Jan. 8, with clusters developing in kindergartens, saunas, bars and churches, mostly in the greater Seoul area.

The country's food and drug safety ministry said on Wednesday it has granted final approval for the use of Johnson & Johnson's (J&J) vaccine after a panel of experts ruled the single-dose shot treatment was safe and effective.

J&J is the third COVID-19 vaccine maker to be authorised in South Korea, after AstraZeneca and Pfizer, both of which require two doses.

Authorities are seeking to speed up a national vaccination campaign despite global supply shortages while expanding preemptive testing and tracing efforts amid concerns over a potential fourth wave of infections. To date, total infections stand at 106,898, with 1,756 deaths.

"If the fourth wave of infections becomes a reality, a disruption to vaccination would be inevitable, as well as dealing a big blow to our economy," Prime Minister Chung Sye-kyun told a government meeting on Wednesday.

"The government is maximising efforts to prevent the fourth wave by mobilising all means possible," he said.

Health officials called on the public to refrain from non-essential gatherings and strictly log visits to crowded venues, such as restaurants, cafes and karaoke bars to facilitate epidemiological work in case of any outbreak.

South Korea is well-equipped with medical resources and enough hospital beds to cover up to 1,000 daily confirmed cases over a 20-day period, Yoon Tae-ho, a senior health ministry official, told a briefing.

"Yet once the fourth wave takes off, there is a possibility the number of patients will spike, so we will continue to secure more beds and take regional measures," said Yoon.

Health authorities also said they will announce new social distancing rules on Friday after discussion with experts and local governments.

The country has so far administered over a million doses of vaccine among medical workers and high-risk groups since the start of its inoculation drive in February, yet authorities face a backlash for relying on the global vaccine-sharing programme COVAX, which has run into delays.

Comments

Comments are closed.